R&G PharmaStudies Balance Sheet Health
Financial Health criteria checks 5/6
R&G PharmaStudies has a total shareholder equity of CN¥1.8B and total debt of CN¥55.1M, which brings its debt-to-equity ratio to 3.1%. Its total assets and total liabilities are CN¥2.3B and CN¥510.0M respectively. R&G PharmaStudies's EBIT is CN¥93.4M making its interest coverage ratio -4. It has cash and short-term investments of CN¥1.7B.
Key information
3.1%
Debt to equity ratio
CN¥55.14m
Debt
| Interest coverage ratio | -4x |
| Cash | CN¥1.74b |
| Equity | CN¥1.79b |
| Total liabilities | CN¥510.02m |
| Total assets | CN¥2.30b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 301333's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥444.7M).
Long Term Liabilities: 301333's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥65.3M).
Debt to Equity History and Analysis
Debt Level: 301333 has more cash than its total debt.
Reducing Debt: 301333's debt to equity ratio has increased from 0% to 3.1% over the past 5 years.
Debt Coverage: 301333's debt is well covered by operating cash flow (306.1%).
Interest Coverage: 301333 earns more interest than it pays, so coverage of interest payments is not a concern.